Elanco Animal Health Inc (ELAN) — SEC Financial Statements & Analysis

Elanco Animal Health Inc (ELAN) is a pharmaceutical preparations company. Elanco Animal Health Inc trades on NYSE as: ELAN. Elanco Animal Health Inc (ELAN)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-05. Based on that filing, Elanco Animal Health Inc carries a market cap of $12.29B, a P/E ratio of -61.77x, a P/B ratio of 1.87x, a P/S ratio of 2.45x, an enterprise value of $15.68B, and an EV/EBITDA multiple of 29.75x. On profitability, it posts a gross margin of 55.36%, an operating margin of -3.31%, a net margin of -3.96%, a Return on Equity (ROE) of -2.98%, a Return on Assets (ROA) of -1.46%, and a Return on Invested Capital (ROIC) of -1.61%. Per share, it reports EPS of $-0.40, diluted EPS of $-0.39, free cash flow per share of $0.76, and a dividend per share of $0.00. Over the trailing year, it posted revenue growth of 11.95% year-over-year, net income growth of -145.85% year-over-year, and EPS growth of -145.59% year-over-year. On the balance sheet, it maintains a current ratio of 2.05x, a quick ratio of 0.91x, working capital of $1.95B, a debt-to-equity ratio of 1.06x, a debt ratio of 0.51, an interest coverage ratio of 11.22x, free cash flow of $379.00M (TTM), and net debt of $3.39B. Figures sourced from SEC EDGAR.

Market Cap

$12.29B

P/E TTM

-61.77x

EPS TTM

$-0.40

P/B TTM

1.87x

ROE TTM

-2.98%

ROA TTM

-1.46%

Debt To Equity

1.06x

Free Cash Flow TTM

$379.00M

Net Revenue TTM Growth 1Y

11.95%

Data as of 2026-06-30 · Source: SEC EDGAR